سعر تاسيجنا 150مجم 28 كبسولة 2024

Nilotinib 150 mg hard capsules (Novartis), a BCR-ABL tyrosine kinase inhibitor for Philadelphia chromosome-positive CML; pack of 28 capsules.

• Adult and paediatric (>=1 year) patients with newly diagnosed Ph+ CML in chronic phase.DailyMed (U.S. National Library of Medicine)
• Adults with chronic or accelerated phase Ph+ CML resistant or intolerant to prior therapy including imatinib; paediatric patients >=1 year resistant/intolerant to prior TKI therapy.DailyMed (U.S. National Library of Medicine)

• Hypokalaemia, hypomagnesaemia or long QT syndrome.International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: QT prolongation and sudden deaths; correct hypokalaemia/hypomagnesaemia before and during therapy and obtain ECGs at baseline, 7 days after initiation, periodically and after dose changes.International label, same product · DailyMed (U.S. National Library of Medicine)
• Myelosuppression, cardiac and arterial vascular occlusive events, pancreatitis/elevated lipase, hepatotoxicity and hyperbilirubinaemia may occur.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A inhibitorsIncrease nilotinib exposure; avoid, or reduce Tasigna dose if unavoidable.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A inducersAvoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Proton pump inhibitorsUse short-acting antacids or H2 blockers instead of PPIs.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on animal data and mechanism; pregnancy test before treatment and effective contraception are advised for females of reproductive potential.International label, same product · DailyMed (U.S. National Library of Medicine)
• Advise women not to breastfeed during treatment and for 14 days after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Nilotinib: Inhibits BCR-ABL kinase by binding and stabilising the inactive conformation of the ABL kinase domain (US label 12.1).